Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Arqit Quantum Inc. - Warrants
Chartwell Retirement Resd
Emera
Pasofino Gold Ltd
Sherritt International Corporation
Solaris Resources Inc. Common Shares
Edit Watchlist
Top Indices
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
My Portfolio
Articles published by Lixte Biotechnology Holdings, Inc.
LIXTE BIOTECHNOLOGY ANNOUNCES APPROVAL OF A PHASE 1B/2 RANDOMIZED TRIAL OF DOXORUBICIN +/-LB-100 IN ADVANCED SOFT TISSUE SARCOMAS TO BE CONDUCTED BY THE SPANISH SARCOMA GROUP
October 13, 2022
From
Lixte Biotechnology Holdings, Inc.
Via
GlobeNewswire
Tickers
LIXT
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.